A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H. Petersdorf, Frederick R. Appelbaum, Kenneth J. Kopecky et al.|Blood|2013Cited by 632
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Richard D. Press et al.|Cancer Cell|2014Cited by 366
Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosisAna Zovko, Leif Stenke|Oncology Reports|2018Cited by 25
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register studyTorsten Dahlén, Leif Stenke, Gustaf Edgren et al.|American Journal of Hematology|2022Cited by 15
Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Johan Richter, Fredrik Sandin et al.|British Journal of Haematology|2021Cited by 15